- Home
- ADN vs LYRA Comparison
ADN vs LYRA Comparison
Compare ADN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- LYRA
- Stock Information
- Founded
- ADN 2006
- LYRA 2005
- Country
- ADN United States
- LYRA United States
- Employees
- ADN N/A
- LYRA N/A
- Industry
- ADN Power Generation
- LYRA Medical/Dental Instruments
- Sector
- ADN Utilities
- LYRA Health Care
- Exchange
- ADN Nasdaq
- LYRA Nasdaq
- Market Cap
- ADN 6.6M
- LYRA 5.8M
- IPO Year
- ADN N/A
- LYRA 2020
- Fundamental
- Price
- ADN $2.90
- LYRA $24.28
- Analyst Decision
- ADN
- LYRA Buy
- Analyst Count
- ADN 0
- LYRA 2
- Target Price
- ADN N/A
- LYRA $100.00
- AVG Volume (30 Days)
- ADN 23.4K
- LYRA 1.9M
- Earning Date
- ADN 12-27-2024
- LYRA 05-06-2025
- Dividend Yield
- ADN N/A
- LYRA N/A
- EPS Growth
- ADN N/A
- LYRA N/A
- EPS
- ADN N/A
- LYRA N/A
- Revenue
- ADN $3,276,000.00
- LYRA $1,185,000.00
- Revenue This Year
- ADN $2,232.99
- LYRA N/A
- Revenue Next Year
- ADN $91.56
- LYRA $1,286.17
- P/E Ratio
- ADN N/A
- LYRA N/A
- Revenue Growth
- ADN 274.35
- LYRA N/A
- 52 Week Low
- ADN $1.71
- LYRA $3.81
- 52 Week High
- ADN $8.79
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- ADN 55.41
- LYRA 76.38
- Support Level
- ADN $2.52
- LYRA $22.22
- Resistance Level
- ADN $2.74
- LYRA $27.42
- Average True Range (ATR)
- ADN 0.26
- LYRA 4.12
- MACD
- ADN 0.07
- LYRA 2.36
- Stochastic Oscillator
- ADN 84.51
- LYRA 60.76
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.